Syntonix, Biovitrum deal

Swedish Orphan Biovitrum AB (SSE:SOBI, Stockholm, Sweden) exercised an opt-in right from Biogen Inc. (NASDAQ:BIIB, Cambridge, Mass.) to take over development and commercialization of Alprolix in Europe, North Africa, Russia and 13 Middle Eastern countries. Pending European regulatory approval of Alprolix, Swedish Orphan will pay Biogen $10 million for exercising the right. Swedish Orphan will also reimburse Biogen Idec about $201 million for incurred costs. In June, EMA accepted for review an MAA for Alprolix to treat hemophilia B (see BioCentury, June 29). ...